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Abstract
Background: Mesenchymal stem cells (MSCs) are of great interest in bone regenerative medicine due to their
osteogenic potential and trophic effects. However, challenges to large-scale production of MSCs can hinder the
translation of MSC therapies. 3D Microcarrier (MC)-based MSC culture presents a scalable and cost-effective
alternative to conventional methods of expansion in 2D monolayers. Furthermore, biodegradable MCs may allow
for MC-bound MSC delivery without enzymatic harvest for selected applications such as bone healing. However,
the effects of cell expansion on microcarriers and enzymatic cell harvest on MSC phenotype and osteogenic
differential potential are not well understood. In this study, we characterized human fetal MSCs (hfMSCs) after
expansion in 3D microcarrier spinner or 2D monolayer cultures. Following expansion, we compared osteogenic
differentiation of cultures seeded with 3D MC-harvested, 3D MC-bound and conventional 2D monolayer (MNL)-harvested
cells when cultured in osteogenic induction media on collagen-coated plates.
Results: Fetal MSCs expanded on both 3D agitated Microcarriers (MC) and 2D Plastic static monolayer (MNL) cultures
express high levels of MSC surface markers. MC-harvested hfMSCs displayed higher expression of early osteogenic genes
but slower mineralization kinetics compared to MNL-harvested MSCs during osteogenic induction. However, in the
comparison between MC-bound and MC-harvested hfMSCs, osteogenic genes were upregulated and mineralization
kinetics was accelerated in the former condition. Importantly, 3D MC-bound hfMSCs expressed higher levels of
osteogenic genes and displayed either higher or equivalent levels of mineralization, depending on the cell line,
compared to the classical monolayer cultures use in the literature (MNL-harvested hfMSCs).
Conclusion: Beyond the processing and scalability advantages of the microcarrier culture, hfMSCs attached to MCs
undergo robust osteogenic differentiation and mineralization compared to enzymatically harvested cells. Thus
biodegradable/biocompatible MCs which can potentially be used for cell expansion as well as a scaffold for direct in
vivo delivery of cells may have advantages over the current methods of monolayer-expansion and delivery
post-harvest for bone regeneration applications.
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Background
Mesenchymal stem cells (MSCs) are cells with the
potential to differentiate into multiple cell types includ-
ing osteoblasts, chondrocytes and adipocytes, and were
shown to have trophic effects, modulate immune re-
sponses and promote healing in vivo [1]. In particular,
the application of MSCs for bone repair has shown clin-
ical promise and there is continued research interest in
this area [2]. Human fetal bone marrow derived MSCs
(hfMSCs) may be especially well suited for bone healing
applications, as they can be maintained for many pas-
sages, have a faster doubling and greater osteogenic
capacity compared to MSCs from other sources,
such as human umbilical cord-derived and human
adipose tissue-derived MSCs, and support in vivo
bone formation [3–5].
Despite the promise of MSC-based therapies, MSC in-
cidence in donor tissue is low [6, 7], and the estimated
dosages required for clinical efficacy are high, ranging
from 40 to 100 million cells per patient [8]. Therefore,
the commercial viability and clinical translation of MSC
therapies, especially those using allogeneic off-the shelf
strategies, are hindered by challenges of scalable expan-
sion of these cells [8]. Current methods of MSC expan-
sion and production such as using stacked 2D surfaces
as cell attachment substrates have limited scalability, are
labor intensive and are costly when large numbers of
cells are required [9].
One potential method of scalable expansion of MSCs
involves the use of bioreactors for suspension culture
and the use of 150–200 μm beaded microparticles, re-
ferred to as microcarriers, as cell adhesion supports. Re-
cent research indicates that microcarrier/bioreactor
systems which are currently primarily used for vaccine
production may be adapted for MSC culture and may
provide several benefits over current culture methods.
Firstly, 3D microcarrier-based systems are more scalable
than 2D monolayer culture systems, allow for ease of
cell sampling and monitoring, and are efficient in terms
of space and culture media usage [8]. Previous work in
our lab has demonstrated efficient growth and differenti-
ation of MSCs expanded on microcarriers in agitation
culture systems [10]. Secondly, in addition to serving as
support substrates for cell expansion, biodegradable 3D
microcarriers [11–18] may potentially serve as scaffolds
for in vivo MSC delivery for selected applications such
as bone healing, eliminating the need for enzymatic
harvest of MSCs from 3D microcarriers. This would re-
quire the development of biodegradable/biocompatible
microcarriers.
In recent years there has been an increased research
interest in the expansion and differentiation of MSCs or
osteoblast-like cells on various naturally-derived, synthetic
and hybrid 3D microcarriers such as PLGA [11, 12]
ENREF_9, PEG [13], PCL [14], PLA [15], gelatin
[16–18] ENREF 11 ENREF 11 ENREF 11 ENREF 11,
collagen-coated polystyrene [19], gelatin-coated or un-
coated dextran [10, 16, 20–22] ENREF 17 ENREF 17,
charged cellulose [16], decellularized adipose tissue
[23] and calcium phosphates [24, 25]. Microcarrier-
expanded MSCs or microcarrier-laden MSCs have been
combined with other strategies such as growth factor
delivery [11], bioprinting [15], sintering [12], cell-
microcarrier aggregation and perfusion [17] or incorp-
oration into scaffolds or hydrogels [10] to enhance the
cells’ regenerative potential, facilitate in vivo delivery or
fabricate larger tissue constructs. Collectively, these
studies have demonstrated that efficient expansion and
differentiation of MSCs or osteoblast-like cells on
microcarriers is feasible.
However, while much is known about the growth
[16, 26, 27] of MSCs on microcarriers and to a lesser
extent, on the mineralization potential of microcarrier-
expanded cells, fewer studies have compared microcarrier-
expanded cells, both harvested and unharvested, with
conventional 2D monolayer harvested cells [28, 29] ENREF
26 to determine their phenotype and osteogenic differenti-
ation potency. In this study, we expanded human fetal
MSCs (hfMSCs) on 3D commercially-available Cytodex 3
gelatin-coated dextran microcarriers in spinner flasks or as
a control, on 2D tissue culture plastic and gelatin-coated
monolayer surfaces and characterized them. Following the
expansion, we seeded and differentiated 3D Microcarrier-
bound (3D MC-bound), 3D Microcarrier-harvested (3D
MC-harv) and 2D Monolayer-harvested (2D MNL-harv)
hfMSCs on collagen-coated plates or polycaprolactone -tri-
calcium phosphate scaffolds and investigated mineralization
as well as the expression levels of key osteogenic genes
under these conditions. 2D gelatin monolayer-harvested
(2D gelatin-MNL-harv) human fetal MSCs on collagen-
coated plates were also included as controls for the effects
of gelatin on differentiation.
Results
To investigate the effect of microcarrier culturing condi-
tion and enzymatic cell harvesting on hfMSC phenotype
after cell expansion and during osteoblastic differenti-
ation, we expanded hfMSCs on microcarriers and mono-
layer cultures and osteogenically differentiated them
with or without cell harvesting (Fig. 1a).
Characterization of hfMSC expanded in 2D static
monolayer and agitated 3D MC cultures
hfMSCs were expanded on microcarriers in spinner flasks
or 2D plastic flasks in monolayer cultures. Cell seeding
density was 4,444 cells/cm2 for microcarriers (4 cells/bead)
and 1,142 cells/cm2 for plastic monolayers respect-
ively to ensure that both cultures reached confluence
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after 7 days of expansion. Doubling times were 53.4
and 35.1 h for microcarrier and monolayer cultures
respectively. At cell harvest after 7 days of expansion,
the cell densities of hfMSCs were similar for microcarriers
and plastic monolayer (39,352 cells/cm2 and 31,429 cells/
cm2 respectively). At Day 7 of growth, the hfMSCs grew
as monolayers in both MC cultures and 2D flasks, with no
aggregation of MC cultures observed (Fig. 1b). Cytokines
were secreted in 3D MC cultures at higher specific
production rates compared to 2D monolayer cultures. At
Day 7 of expansion, the specific production rates for 3D
MC cultures over 2D monolayer cultures were 249
fold (0.2985 vs 0.0012 pg/cell/day) for IL-6, 4.9-fold
(0.4072 vs 0.0836 pg/cell/day) for IL-8 and 1.8 fold
(0.00618 vs 0.00344 pg/cell/day) for CXCL5 (Fig. 2a,
b and c respectively).
Flow cytometry analysis of cell surface marker expres-
sion showed that 3D MC-harv hfMSCs expressed
equivalent high levels of International Society for Cell
Therapy (ISCT) MSC markers (CD34, CD105, CD73
and CD90) and lower levels of the endothelial, pericyte-
associated marker CD14627,28 and α1 integrin (itgα1)
and higher level of the pro-osteogenic α2 integrin
(itgα2), compared to 2D MNL-harv hfMSCs (Fig. 2d).
FACS data for cell surface marker expression was not
obtained on 3D MC-bound cells because FACS analysis
requires dissociating cells from the microcarriers. qPCR
confirmed that the α2 integrin is upregulated in 3D
MC-harv hfMSCs compared to 2D MNL-harv hfMSCs
(Additional file 1: Figure S4).
In summary microcarrier culture increases the cyto-
kine production rate and changes the expression levels
Fig. 1 a Experimental Design. Human fetal mesenchymal stem cells (hfMSCs) from 2 different donors, denoted as S27 and S127 were cultured in
growth media on Cytodex 3 microcarriers (3D MCs) in a spinner flask or as monolayers on tissue culture plastic flasks for 7 days. Thereafter, cells
on 3D MCs (3D MC-bound), or cells enzymatically harvested from MCs (3D MC-harv) were seeded onto a collagen I-coated plate and differentiated for
14 days. Similarly cells expanded on uncoated (2D MNL-harv) or gelatin-coated (2D gelatin-MNL-harv) monolayer flasks were harvested and differentiated
for 14 days. b Microscopic images of S27 hfMSCs after 7 days of expansion on Cytodex 3 microcarriers
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of some cell surface markers, but not the ISCT MSC
markers.
Effect of hfMSC expansion methods on osteogenic
differentiation (3D MC-harvested vs 2D MNL-harvested cells)
To determine the effect of 3D microcarrier-based cell
expansion on subsequent osteogenic differentiation, we
measured gene expression and calcium deposition during
osteogenic differentiation on collagen-coated 6-well plates
seeded with 3D MC-harvested (3D MC-harv) and 2D
monolayer-harvested (2D MNL-harv) cells. Cells expanded
on 2D gelatin-coated monolayer cultures and enzymatically
harvested (2D gelatin-MNL-harv) served as a control for
the effects of gelatin coating during expansion, as the Cyto-
dex 3 microcarriers are gelatin-coated.
We examined early, and late osteogenic gene marker ex-
pression in hfMSCs undergoing osteogenic induction in
order to study their differentiation potential. Cultures
seeded with 3D MC-harv cells expressed higher levels of
three early osteogenic markers, namely RUNX2, ALPL and
Osterix/ SP7 and one late osteogenic marker, IBSP at a sin-
gle time point (Fig. 3a). Despite the increased expression of
these osteogenic markers, the mineralization of 3D MC-
harv cells displayed slower kinetics compared to 2D MNL-
harv cells. Specifically, 2D MNL-harv cells have 55 %
higher calcium per 106 cells at Day 14 compared to 3D
MC-harv cells (Fig. 3b) and also stain for Alizarin red by
Day 7, while 3D MC-harv cells do not stain at this time-
point (Additional file 2: Figure S2A). The control
culture of 2D gelatin-MNL-harv hfMSCs did not dis-
play enhanced expression of early osteogenic genes
(Runx2, ALPL and Col1a1) when compared with 2D
MNL-harv hfMSCs (Additional file 3: Figure S1A).
This suggests that the enhanced expression of early
osteogenic genes in MC-harv hfMSCs (Fig. 3) is not
due to the effects of the gelatin coating on Cytodex
3 microcarriers but rather to the mode of propagation
(microcarriers in agitated spinner flask vs static MNL cul-
ture). Similar levels of COL1A1, BMP2K, Osteopontin/
SPP1, Osteocalcin/BGLAP and SPARC gene expression
level were observed in 3D MC-harv and 2D MNL-harv
cells (Fig. 3a).
In agreement with results on the collagen-coated
plates, on PCL-TCP scaffolds, 3D MC-harv cells also
displayed increased expression of early (Runx2 and
ALPL) but not late osteogenic markers compared to
2D MNL-harv cells (Additional file 4: Figure S3A).
In contrast with observations on the collagen-coated
plates, the decelerated mineralization of 3D MC-harv
cells on 3D PCL-TCP scaffolds were not as apparent
based on Alizarin Red staining compared to 2D
MNL-harv cells (Additional file 2: Figure S2B).
Fig. 2 Phenotype of S27 hfMSCs expanded on 2D MNL or on Cytodex 3 microcarriers (3D MC) in a spinner flask. Profile of cytokine production
rates for (a) IL-6, (b) IL-8 and (c) CXCL5 as measured by ELISA during the 7-day expansion. d Cell surface marker expression of MSC harvested
from 2D MNL and 3D MC expanded cultures measured by flow cytometry. *p < 0.05 for 3D MC-harv compared to 2D MNL-harv by 2-tailed t-test
in Graphpad
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Fig. 3 Kinetics of gene expression, cell growth and calcium deposition during osteogenic differentiation of collagen I-coated plates seeded with
microcarrier-harvested (3D MC-harv) or 2D monolayer-harvested (2D MNL-harv) S27 hfMSCs. a Osteogenic gene expression, early and late markers.
Values normalized to Day 0 post-differentiation (*p < 0.05 and >2-fold difference). N = 3 biological replicates per condition. b Cell growth (cell
density in 105 cells/cm2) (left) and calcium deposition per 106 cells (right), (*p < 0.05). N = 3 biological replicates per condition. Two-way repeated
measures ANOVA with post-hoc Tukey correction was performed between 3D MC-harv and 2D MNL-harv and MC-bound cells using Graphpad.
Of the multiple comparisons performed, data representing a single comparison (2D MNL-harv vs 3D MC-harv) is shown in this figure
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Effect of hfMSC harvesting on osteogenic differentiation
(3D MC-bound vs 3D MC-harv cells)
To investigate the effect of cell harvesting on hfMSC
osteogenic differentiation, we compared the kinetics of
osteogenic gene expression and calcium mineralization
during the differentiation process carried out in 6-well
plates seeded with 3D MC-bound and 3D MC-harv
hfMSCs.
We found that cultures seeded with 3D MC-bound
cells showed increased expression of early osteogenic
markers such as RUNX2, ALPL, and COL1A1 as well as
some late markers such as Osteopontin/ SPP1 and IBSP
(Fig. 4a) compared to 3D MC-harv cells. Consistent with
the increased expression of both early and late osteo-
genic genes, mineralization was accelerated in 3D MC-
bound cells compared to 3D MC-harv cells (Fig. 4b).
The calcium production rate was 1.5 to 3.8 fold higher
in 3D MC-bound cell cultures as compared to 3D MC-
harv cells. It is important to note that the calcium
deposition occurred in foci surrounding the seeded 3D
MC-bound cells as shown by the Alizarin red staining
on day 7 and 14 (Additional file 2: Figure S2A) suggest-
ing that hfMSCs attached to microcarriers have a higher
mineralization potential.
Comparison of efficiency of osteogenic differentiation
(3D MC-bound vs 2D MNL-harv hfMSCs)
Because the conventional method of in vitro expansion
and MSC delivery involves cell culture on 2D tissue culture
plastic monolayers (usually in cell stacks), we compared
the osteogenic potential of 3D MC-bound cells to 2D
MNL-harv cells. A control culture, 2D gelatin-MNL-harv
hfMSCs, was added as previously discussed. 2D gelatin-
MNL-harv hfMSCs did not show enhanced osteogenic
gene expression or increased calcium deposition compared
to either 3D MC-bound or 2D MNL-harv hfMSCs for 2
hfMSC cell lines, S27 and S127 (Additional file 3: Figure
S1), showing that the gelatin coating during cell expansion
do not affect osteogenic differentiation. In 3D MC-bound
S27 cells differentiated on 6-well plates, gene expression
levels of all 9 markers tested were elevated compared to
2D MNL-harv cells, in many cases at more than one time
point (Fig. 5a). The genes that were upregulated in 3D
MC-bound cells included early markers such as RUNX2,
ALPL, COL1A1, Osterix/ SP7 and medium to late markers
such as BMP2K, Osteopontin/SPP1, IBSP, Osteocalcin/
BGLAP and SPARC (Fig. 5a). Although osteogenic gene
expression levels were higher in 3D MC-bound cells
during differentiation, for the S27 line, calcium deposition
levels were equivalent to 2D MNL-harv cells as measured
by calcium assay (Fig. 5b) and qualitative Alizarin Red
staining (Additional file 2: Figure S2A).
When S27 hfMSCs were osteogenically induced on
PCL-TCP scaffolds, 3D MC-bound S27 hfMSCs similarly
expressed higher levels of RUNX2, ALPL, COL1A1,
however there was no difference in the expression levels
of Osteopontin/SPP1 and Osteocalcin/ BGLAP (Additional
file 4: Figure S3B). While mineralization on collagen plates
was merely equivalent between 3D MC-bound and 2D
MNL-harv cells, on PCL-TCP scaffolds, 3D MC-bound
cells displayed accelerated mineralization compared to 2D
MNL-harv cells (Additional file 2: Figure S2B).
In order to confirm the biological significance of our
findings, we repeated our experiment with a second
hfMSC line known as S127. 3D MC-bound S127
hfMSCs showed upregulated gene expression of both
early (Runx2, ALPL, Osteocalcin/BGLAP) and late
markers (SPARC) (Additional file 3: Figure S1A) com-
pared to 2D MNL-harv cells, confirming the result that
was seen with 3D MC-bound S27 hfMSCs. Furthermore,
3D MC-bound S127 hfMSCs showed improved calcium
deposition per million cells compared to 2D MNL-harv
(Additional file 3: Figure S1B).
Discussion
Fetal MSCs are may be a suitable MSC source for bone
healing applications, as they have greater osteogenic cap-
acity than umbilical cord- and adipose tissue-derived
MSCs [3], and support in vivo bone formation [3–5].
The expansion of MSCs on microcarriers in bioreactors
provides several advantages over current monolayer cul-
ture methods. These include scalability of culture in a
cost effective manner [9], and the potential ability to de-
liver cells post-expansion without a cell harvesting step
on biodegradable microcarriers [11, 12] for selected ap-
plications such as cartilage and bone healing. However,
the effects of MSC culture in microcarrier/bioreactor
systems and subsequent harvesting on cell phenotype
and differentiation potential is not well understood.
hfMSCs cultured on 3D microcarriers versus 2D
monolayer displayed a higher specific production rate of
the pro- and anti-inflammatory and immunoregulatory
[30] cytokine IL-6 [31] which maintains stemness in MSCs
[32], the pro-angiogenic chemokine IL-8 [33, 34] and
CXCL5, a chemokine which attracts leukocytes as well as
hematopoietic stem cell migration[35]. These results sug-
gest that the use of microcarrier-expanded hfMSCs in
immunoregulatory or angiogenic therapies may provide
greater benefits than with standard 2D MNL-harv cells.
However, further experiments will be required to establish
if this is the case with in vitro potency assays.
The high expression levels of ISCT MSC markers in
hfMSCs expanded in both stirred 3D MC and 2D MNL
cultures indicate that the mode of expansion did not alter
the MSC-like phenotype of the hfMSCs. However, we ob-
served a downregulation of CD146, an endothelial and
pericyte marker, in 3D MC-expanded cells, and this effect
also occurs in MSCs in spheroid culture [36], suggesting
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Fig. 4 (See legend on next page.)
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that the decrease in CD146 expression may be a response
to the suspended nature of the cell culture.
Osteogenically induced cultures seeded with 3D MC-
harv hfMSCs showed increased expression of early osteo-
genic genes and decelerated mineralization kinetics com-
pared to 2D MNL-harv hfMSCs. While the reasons for this
effect is unknown, possible factors involved may include
differences in the cell microenvironment during expansion
including substrate stiffness, shear forces due to agitation
culture, or adhesion to a curved versus flat surface.
3D MC-bound hfMSCs showed improved osteogenic
differentiation compared to both 3D MC-harv (Fig. 4,
S2A) and 2D MNL-harv hfMSCs (Fig. 5, Additional file
3: Figure S1A & B, Additional file 2: Figure S2A & B and
Additional file 4: Figure S3B). 3D MC-bound show in-
creased expression of some early (Fig. 4) osteogenic
genes, as well as accelerated mineralization compared to
3D MC-harvested hfMSCs (Fig. 4b, Additional file 2:
Figure S2A). However, our most important finding was
the enhanced differentiation of 3D MC-bound hfMSCs
compared to 2D MNL-harv hfMSCs. Gene expression of
osteogenic markers was elevated in 3D MC-bound S27
and S127 hfMSCs compared to 2D MNL-harv cells (Fig. 5a,
Additional file 3: Figure S1A). Furthermore, 3D MC-bound
hfMSCs showed equivalent (S27) (Fig. 5b) or enhanced cal-
cium deposition (S127) (Additional file 3: Figure S1B) com-
pared to 2D MNL-harv cells, which represent the industry
standard method of cell expansion. These results confirm
previous work from our lab which demonstrate that
microcarrier-expanded and microcarrier-bound hfMSC
undergo efficient mineralization [10].
The improved differentiation of 3D MC-bound hfMSCs
could be explained by a number of factors include the lack
of disruption of ECM-integrin or cell-cell contacts, or the
localized regions of high cell confluency on and around the
microcarriers. In support of the first explanation, ECM-
integrin [37, 38] interactions play an important role in
directing cell fate and we observed large differences in in-
tegrin gene expression between the 3D MC-bound and 3D
MC-harv cells (Additional file 1: Figure S4). However, we
also note that for 3D MC-bound hfMSC samples, Alizarin
Red staining was higher on the cells attached to the micro-
carriers than on the cells which migrated off the microcar-
riers and onto the collagen-coated plate surface (Additional
file 2: Figure S2A), suggesting that some aspect of the cell-
microcarrier interaction enhances mineralization, in sup-
port of the second explanation. Our findings of enhanced
osteogenic differentiation on 3D MC-bound hfMSCs raise
questions of mechanism. The upregulation of osteogenic
genes in 3D MC-bound hfMSCs over both 2D MNL-harv
and 2D gelatin-MNL-harv hfMSCs, combined with the lack
of enhancement in differentiation between gelatin coated
and uncoated MNL-harv cells suggest that the results seen
in 3D MC-bound hfMSCs are not due to the gelatin coat-
ing on Cytodex 3 microcarriers.
If the same enhancement of osteogenic differentiation
occurs on other types of biodegradable/ biocompatible
microcarriers, the expansion and delivery of hfMSCs on
these microcarriers may offer multiple advantages over
current methods of MSC expansion in 2D monolayer and
harvesting prior to in vivo delivery for selected applications
such as bone tissue engineering. These advantages include
cost-efficient and large-scale production of hfMSCs in con-
trolled bioreactors, as well as the potential elimination of
the cell harvested process for select in vivo applications,
enabling faster and lower cost MSC bioprocessing.
Conclusion
This study indicates that hfMSCs which are cultured on
3D microcarriers in agitation culture and remain attached
to Cytodex 3 gelatin-coated dextran microcarriers (3D
MC-bound) during osteogenic induction show enhanced
osteogenic differentiation compared to hfMSCs which are
cultured under static conditions on 2D monolayer surfaces
and are harvested prior to differentiation (2D MNL-harv).
If these results also occur in biodegradable/biocompatible
microcarriers, the method of microcarrier-expansion and
in vivo delivery of 3D MC-bound hfMSCs may be a prom-
ising strategy which should be further evaluated for in vivo
bone healing.
Methods
hfMSC expansion in spinner flasks and tissue culture
plastic flasks
Fetal bone marrow derived MSCs were obtained from
Dr Jerry Chan, NUS. These cells were harvested from
fetal tissue with the approval of the institutional domain
specific review board (NHG DSRB 2006/00154) and inter-
national guidelines regarding the use of fetal tissue for
research purposes as previously described [5]. Pregnant
(See figure on previous page.)
Fig. 4 Kinetics of gene expression, early and late markers, cell growth and calcium deposition during osteogenic differentiation of collagen
I-coated plates seeded with microcarrier-harvested (3D MC-harv) or microcarrier-bound (3D MC-bound) S27 hfMSCs. a Osteogenic gene
expression values normalized to Day 0 post-differentiation (*p < 0.05 and >2-fold difference). N = 3 biological replicates per condition. b Cell
growth (cell density in 105 cells/cm2) (left) and calcium deposition per 106 cells (right), (*p < 0.05). N = 3 biological replicates per
condition. Two-way repeated measures ANOVA with post-hoc Tukey correction was performed between 3D MC-harv, 2D MNL-harv and
3D MC-bound cells using Graphpad. Of the multiple comparisons performed, data representing a single comparison (3D MC-bound vs 3D
MC-harv) is shown in this figure
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Fig. 5 Kinetics of gene expression, early and late markers, cell growth and calcium deposition during osteogenic differentiation of collagen I-coated
plates seeded with monolayer-harvested (2D MNL-harv) or microcarrier-bound (3D MC-bound) S27 hfMSCs. a Osteogenic gene expression values
normalized to Day 0 post-differentiation (*p < 0.05 and >2-fold difference). N = 3 biological replicates per condition. b Cell growth (cell density in
105 cells/ cm2) (left) and calcium deposition per 106 cells (right), (*p < 0.05). N = 3 biological replicates per condition. Two-way repeated measures
ANOVA with post-hoc Tukey correction was performed between 3D MC-harv, 2D MNL-harv and 3D MC-bound cells using Graphpad. Of the multiple
comparisons performed, data representing a single comparison (3D MC-bound vs 2D MNL-harv) is shown in part (a) and (b) in this figure
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women gave written consent for the procedure and the
use of fetal tissue for research purposes. All fetal tissues
were collected from fetuses after clinically indicated ter-
mination of pregnancy. Fetal bone marrow derived MSCs
from two different donors were used in this study and
these MSCs are referred to as S27 and S127. Cytodex 3
microcarriers (MCs), GE Healthcare, were prepared ac-
cording to manufacturer’s instructions. Briefly, MCs were
washed with PBS, autoclaved and rinsed in culture media
prior to hfMSC seeding. P6-7 hfMSCs were seeded on ei-
ther Cytodex3 MCs or T175 tissue culture plastic flasks.
8 mg/ml Cytodex3 MCs were seeded in 100 ml spinner
flasks (Scientific Industries) at a density of 4 cells/micro-
carrier and stirred at 25 rpm overnight. Thereafter, the im-
peller rotation speed was increased to 30 rpm. hfMSCs
were seeded at a density of 1142cells/cm2 in T175 tissue
culture plastic flasks and cultured under static (no agita-
tion) conditions. α-MEM medium supplemented with
10 % FBS, 1 % penicillin-streptomycin was used. Micro-
carrier cultures were fed by 50 % media change because it
is technically challenging to perform full media changes
without removing settled microcarriers. Full media
changes were performed for plastic monolayer cultures
every 2–3 days according to standard practice [10]. Cells
were harvested after 7 days of expansion by enzymatic
harvesting from microcarriers, 44 ml of 0.25 % Trypsin-
EDTA (Gibco) was added to 800 mg of Cytodex 3 micro-
carriers which have a total surface area of 2160 cm2
(0.02 ml trypsin/cm2 growth area). After 15 min of incu-
bation, trypsin was quenched with fresh growth media,
and the microcarriers were separated from the cell sus-
pension using a 40um cell strainer (Greiner). Cells in
T175 plastic monolayer were trypsinized by rinsing with
5 ml PBS followed by 5 min of incubation with 4 ml of
0.25 % Trypsin-EDTA (0.02 ml trypsin/cm2 surface area)
and quenching with 8 mls of growth media. The viable cell
count in the cell suspension was obtained using the
Nucleocounter (Chemometec) according to the manufac-
turer’s instructions. The average doubling time of the cells
during the 7 day (168 h) expansion was calculated using
the following equation:
Td = (t2-t1) × log(2)/log(c2/c1) or Td (hours) = 168 h ×
log(2)/log(c2/c1)
where Td is doubling time, t2 is the final timepoint, t1
is the initial timepoint, c2 is the final cell count and c1 is
the initial cell count.
Differentiation of expanded hfMSCs on collagen-coated
plates or PCL-TCP scaffolds
Cells were obtained post-expansion for seeding and
differentiation in one of 3 ways (Fig. 1):
1) 3D microcarrier-expanded cells were not enzymati-
cally harvested, but left attached to microcarriers
and these cell-laden microcarriers were seeded (3D
MC-bound)
2) 3D microcarrier-expanded cells were enzymatically
harvested and seeded (3D MC-harv)
3) 2D uncoated monolayer tissue culture plastic
flask-expanded cells were enzymatically harvested
and seeded (2D MNL-harv)
4) 2D gelatin-coated monolayer plastic flask-expanded
cells were enzymatically harvested and seeded (2D
gelatin-MNL-harv)
Osteogenic differentiation was carried out in two
systems:
1) 2D Collagen-coated 6-well plates
2) 3D PCL-TCP scaffolds
The 6-well plates were coated for 1 h at 37 °C with
0.01 % rat-tail collagen I (BD Biosciences). 6 well plates
were then seeded with 200,000 hfMSCs per well. PCL-
TCP scaffolds were obtained from Osteopore Inter-
national were cut into 4 × 4 × 10 mm scaffolds and
treated by rinsing in NaOH and washed three times in
PBS. Scaffolds were seeded with 200,000 hfMSCs per
scaffold.
After seeding, hfMSCs were cultured in osteogenic in-
duction media as shown previously[10] (DMEM (Gibco)
supplemented with 10 % FBS, 1 % penicillin-streptomycin,
10nM dexamethasone, 10 mM β-glycerophosphate and
0.2 mM ascorbic acid). We have used this osteogenic in-
duction media formulation in previously published work
with hfMSCs [10].
Cell counting, surface marker flow cytometry
Cell counts of attached cells were performed by trypsini-
zation of cells on 6-well plates or PCL-TCP scaffolds
followed by nuclei counting according to the manufac-
turer’s instructions using the Nucleocounter NC-100,
Chemometec. Cell counts were performed from 3 separ-
ate 6-wells within the same experiment (n = 3) for each
condition tested. For flow cytometry, cells were trypsi-
nized, resuspended in flow cytometry buffer (PBS/0.1 %
BSA) and incubated with primary antibodies for 20 min,
followed by incubation with a FITC-conjugated polyclonal
rabbit anti-mouse secondary antibody for 15 min and ana-
lyzed on a GUAVA easyCyte HT sampling flow cytometer,
Merck Millipore. We used anti-human primary antibodies
for CD34, CD73, CD146, CD29 (itgβ1), CD49e (itgα5),
CD49b (itgα2), CD49a (itgα1), CD51/61(itgαvβ3) and
CD49f (itgα6) (Biolegend), CD90 (Millipore), CD105 (Invi-
trogen). We used the manufacturer’s recommended anti-
bodies used as isotype controls (either mouse IgG1, IgG2a
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or IgG2b, or rat IgG2a from Biolegend or mouse IgG1
from Millipore).
Measurement of cytokine production
Cytokine concentration (IL-6, IL-8 and CXCL-5) in cul-
ture supernatants were measured at days 0, 3, 4, 5, 6 and
7 using ELISA kits from R&D systems (Minneapolis,
MN) according to the manufacturer’s instructions.
Supernatant was obtained from 1 spinner flasks or T-
flasks per condition (n = 1). For each time point, calcula-
tions were made using the formula below:
Specific cytokine production rate at Day n pg=cell=dayð Þ




Total RNA was extracted from hfMSCs propagated in 6-
well plates or scaffds by Trizol-chloroform extraction.
RNA was extracted from 3 separate 6-wells within the
same experiment (n = 3) for each condition tested. The
RNA was purified using an RNeasy Mini kit (Qiagen)
with on-column DNA digestion according to the manu-
facturer’s instructions. 0.5ug of total RNA was used to
perform cDNA synthesis in 20ul total volume using a
Maxima First Strand cDNA synthesis kit (Thermo Scien-
tific). Quantitative PCR was carried out using Taqman
Gene Expression Assays (Life Technologies) using the
gene expression assays listed below. GAPDH was used
as the housekeeping gene. The ID numbers for specific
genes assayed using the Taqman Gene Expression Assay
system are listed in Additional file 5: Table S1.
Calcium deposition assay
Cells cultured on 6-well plates were rinsed with PBS
three times and incubated with 0.5 N acetic acid for 1 h
at room temperature to allow for calcium elution. Cal-
cium was eluted from cells from 3 different wells per
condition tested within the same experiment (n = 3).
The calcium concentrations in the acetic acid samples
were quantified using a calcium assay kit (BioAssay Sys-
tem) according to the manufacturer’s instructions. Final
calcium concentration was determined after background
subtraction of Day 0 values.
Alizarin red staining
Differentiating cultures (in 6-well plates or scaffolds)
were fixed with 4 % paraformaldehyde for 1 h at room
temperature. Thereafter, cells were stained with 1 ml of
2 % alizarin red (Sigma), pH 4.2 solution for 1 h at room
temperature, rinsed with PBS three times and imaged
using an Evos light microscope. 3 different wells were
stained per condition and a representative image is
shown for each condition.
Statistical analysis
Data are presented as mean and standard error. Statistical
analysis was performed by one-way ANOVA with post-
hoc Tukey (for data at a single time point) or two-way re-
peated measures ANOVA with post-hoc Tukey (for time
course data) to compare between more than two groups.
A p-value of less than 0.05 was considered significant. For
gene expression data, a difference between two groups
was considered significant if the p-value was less than 0.05
and there was a 2-fold or greater difference between the
mean values for those groups. Statistical analysis was per-
formed using Graphpad Prism software.
Additional files
Additional file 1: Figure S4. Gene expression of anti-inflammatory,
Wnt inhibition, YAP/TAZ targets and integrins S27 hfMSCs after 7 days
of expansion in 2D monolayer-harvested cultures (2D MNL-harv) and
harvested and non-harvested 3D MC cultures (3D MC-bound and 3D
MC-harv respectively). Results are presented as fold expression levels of
genes compared to 2D MNL-harv (*p < 0.05 and at least a 2-fold difference
in the means compared to 2D MNL-harv, ($ p < 0.05 and at least a 2-fold
difference in the means compared to 3D MC-harv). (TIFF 609 kb)
Additional file 2: Figure S2. Calcium deposition measured by Alizarin
red staining during osteogenic differentiation of cultures seeded with 2D
MNL-harvested, 3D MC-harv and 3D MC-bound S27 hfMSCs.
(A) Collagen-coated 6-well plates. N = 3 biological replicates per
condition, one representative image is shown per condition.
(B) PCL-TCP scaffolds, (left) side view, (right) top view of scaffolds.
N = 3 biological replicates per condition, one representative image
is shown per condition. (TIFF 1729 kb)
Additional file 3: Figure S1. Gene expression measured by qPCR and
normalized calcium deposition at Day 14 post-osteogenic induction for 3D
MC-bound, 2D MNL-harv and 2D gelatin-MNL-harv hfMSCs. (A) Osteogenic
gene expression for S127 hfMSCs (*p < 0.05 and >2-fold difference vs 2D
MNL-harv, $ p < 0.05 and >2-fold difference vs 2D gelatin-MNL-harv,). N = 3
biological replicates per condition. (B) Calcium deposition per million cells
for S27 and S127 hfMSCs (*p < 0.05). Comparison between MC-bound to
the 2 controls MNL-harv and gelatin-MNL-harv. For both (A) and (B) ANOVA
with post-hoc Tukey was performed using Graphpad. (TIFF 303 kb)
Additional file 4: Figure S3. Kinetics of osteogenic gene expression
during osteogenic differentiation of S27 hfMSC in PCL-TCP scaffold
cultures. (A) Cultures seeded with 2D monolayer-harvested (2D MNL-harv)
and microcarrier-harvested (3D MC-harv) cells, (B) Cultures seeded with
microcarrier-harvested (2D MNL-harv) and microcarrier-bound (3D MC-bound)
cells. Two-way repeated measures ANOVA with post-hoc Tukey correction
was performed between 3D MC-harv, 2D MNL-harv and 3D MC-bound cells
using Graphpad, (*p< 0.05 and at least a 2-fold difference in the means). Of
the multiple comparisons performed, data representing a single comparison is
shown: (A) 3D MC-harv vs 2D MNL-harv, (B) 3D MC-bound vs 2D MNL-harv.
(TIFF 544 kb)
Additional file 5: Table S1. List of Taqman Gene Expression Assay IDs
for genes investigated by qPCR in this study. (DOCX 13 kb)
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lactic co-glycolic acid; PEG: Polyethylene glycol; PLA: Poly lactic acid;
MEM: Minimal essential medium; EDTA: Ethylenediaminetetraacetic acid.
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